Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mupirocin,Chlorhexidine
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Bacterial Decolonization Within Dyads
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 07, 2024
Lead Product(s) : Mupirocin,Chlorhexidine
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mupirocin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Alembic Pharmaceuticals Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mupirocin cream USP, 2% is indicated for the treatment of secondarily infected traumatic skin lesions due to susceptible strains of S. aureus and S. pyogenes.
Product Name : Mupirocin
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 17, 2021
Lead Product(s) : Mupirocin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Alembic Pharmaceuticals Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mupirocin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Mupirocin Gel in Children With Impetigo
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 27, 2020
Lead Product(s) : Mupirocin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Doxycycline,Trimethoprim,Sulfamethoxazole,Clindamycin Hydrochloride,Clarithromycin,Ciprofloxacin,Fusidic Acid,Rifampicin,Chlorhexidine,Mupirocin,Povidone Iodine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : ZonMw | Academisch Medisch Centrum - Universiteit van Amsterdam | University College, London
Deal Size : Inapplicable
Deal Type : Inapplicable
S. Aureus Decolonization in HPN Patients.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 01, 2017
Lead Product(s) : Doxycycline,Trimethoprim,Sulfamethoxazole,Clindamycin Hydrochloride,Clarithromycin,Ciprofloxacin,Fusidic Acid,Rifampicin,Chlorhexidine,Mupirocin,Povidone Iodine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : ZonMw | Academisch Medisch Centrum - Universiteit van Amsterdam | University College, London
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mupirocin,Chlorhexidine,Iodophor
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Hospital Corporation of America | University of California, Irvine | University of Massachusetts, Amherst | Rush University | Centers for Disease Control and Prevention
Deal Size : Inapplicable
Deal Type : Inapplicable
Mupirocin-Iodophor ICU Decolonization Swap Out Trial
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 04, 2017
Lead Product(s) : Mupirocin,Chlorhexidine,Iodophor
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Hospital Corporation of America | University of California, Irvine | University of Massachusetts, Amherst | Rush University | Centers for Disease Control and Prevention
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mupirocin,Chlorhexidine
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Clinical Trials Unit Bern | Lindenhofstiftung | Labormedizinisches Zentrum Dr. Risch
Deal Size : Inapplicable
Deal Type : Inapplicable
Preoperative Decolonization and Surgical Site Infections - a Prospective Randomized Trial
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 25, 2015
Lead Product(s) : Mupirocin,Chlorhexidine
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Clinical Trials Unit Bern | Lindenhofstiftung | Labormedizinisches Zentrum Dr. Risch
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mupirocin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 06, 2014
Lead Product(s) : Mupirocin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mupirocin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 25, 2013
Lead Product(s) : Mupirocin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifampicin,Trimethoprim,Sulfamethoxazole,Minocycline Hydrochloride,Mupirocin,Chlorhexidine Gluconate,Chlorhexidine
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : CF Therapeutics Development Network Coordinating Center | Seattle Children’s Hospital | Washington University School of Medicine | University of Washington | University of Colorado, Denver | Baylor College of Medicine | University of Alabama at Birmingham
Deal Size : Inapplicable
Deal Type : Inapplicable
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2011
Lead Product(s) : Rifampicin,Trimethoprim,Sulfamethoxazole,Minocycline Hydrochloride,Mupirocin,Chlorhexidine Gluconate,Chlorhexidine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : CF Therapeutics Development Network Coordinating Center | Seattle Children’s Hospital | Washington University School of Medicine | University of Washington | University of Colorado, Denver | Baylor College of Medicine | University of Alabama at Birmingham
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chlorhexidine Gluconate,Mupirocin,Fusidic Acid,Trimethoprim,Sulfamethoxazole,Doxycycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Alberta Health services
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 02, 2010
Lead Product(s) : Chlorhexidine Gluconate,Mupirocin,Fusidic Acid,Trimethoprim,Sulfamethoxazole,Doxycycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Alberta Health services
Deal Size : Inapplicable
Deal Type : Inapplicable